title: Short- and long-term overall results of liver retransplantation: "Doce de Octubre" hospital experience.
abstract: BACKGROUND
  The liver retransplantation rate in Spain is about 6%. The main causes are primary nonfunction, vascular complications, chronic rejection, and recurrent liver disease. The results of this procedure are worse than those of first transplantations.
  
  
  METHODS
  This retrospective study evaluated our experience with 54 retransplantations performed between January 1992 and December 2006, which were 5.6% of the 960 orthotopic liver transplantations (OLT) during this period.
  
  
  RESULTS
  In this study, 34.7% of the retransplantations were performed between 4 and 30 days after the first transplantation; another 34.7% were within 1 year. Also, 48.9% of the retransplantations were performed in urgent situations. The main causes for retransplantation during the first month were primary hepatic failure (n = 14) and vascular complications (n = 4). After the first month the main causes were chronic rejection (n = 9), recurrence of hepatic disease (n = 3), and biliary complications (n = 4). Postoperative mortality was 23.9% and morbidity was 76.3%. However, 21.2% of the patients needed a third transplant. The overall rate of patient survival was 60.4% (n = 32) and of graft survival was 56.6% (n = 30). The 5-year actuarial graft survival rate was 65.4% with a mean survival time of 89.84 +/- 8.72 months; the 5-year patient survival rate was 64% with a mean survival time of 114.7 +/- 12.53 months. Worse survival was observed in chronic rejection and in retransplantations performed between 31 and 360 days.
  
  
  CONCLUSIONS
  Liver retransplantation presents greater surgical complexity than the first transplantation, but is a good option for patients with failure of the first graft with a 5-year patient and graft survival rate greater than 65%.
authors.affiliation: General, Digestive and Abdominal Organs Transplant Surgical Department, 12 de Octubre Hospital, Madrid, Spain. perezsb@hotmail.com
authors.forename: B
authors.initials: B
authors.lastname: Pérez-Saborido
authors.forename: J C
authors.initials: JC
authors.lastname: Menéu-Díaz
authors.forename: S Jiménez
authors.initials: SJ
authors.lastname: de los Galanes
authors.forename: V
authors.initials: V
authors.lastname: Barra
authors.forename: Y
authors.initials: Y
authors.lastname: Fundora
authors.forename: M
authors.initials: M
authors.lastname: Abradelo
authors.forename: A
authors.initials: A
authors.lastname: Gimeno
authors.forename: V
authors.initials: V
authors.lastname: Molinero
authors.forename: M
authors.initials: M
authors.lastname: Sanz
authors.forename: M C
authors.initials: MC
authors.lastname: Fernández
authors.forename: C
authors.initials: C
authors.lastname: Jiménez
authors.forename: E
authors.initials: E
authors.lastname: Moreno González
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D016031:Liver Transplantation / Q000401:mortality / Q000502:physiology* / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D012086:Reoperation / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D015996:Survival Rate; D017741:Survivors; D017211:Treatment Failure